Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc
Bullboard Posts
User Avatar Image
(31)
•••
Comment by stanleyon Dec 29, 2011 10:51am
296 Views
Post# 19356659

RE: Interesting data...........

RE: Interesting data...........

Another link (found at Yahoo board)

https://stockcharts.com/h-sc/ui?s=BRD&p=D&st=2011-12-22&en=%28today%29&id=p40325945836

Someone over at Yahoo keeps looking back as past missed targets. In mining, missed targets are the norm, unless you have severely understimated the production capacity of the system. WHen a company is taken over it takes time for some of the "bottle-necks" to emerge (people & systems).

A reasonable amount of time has passes to enable WD/RA to make their assessments and introduce the appropriate correctrive measures.

BWDIK? Is the stock being externally influences or is the Euro related. The U$ peso is in a dead cat bounce as a result of the Euro devaluation. This will rebalance in time. SO will BRD (mid-morning) of the last day of the week folling TLS? Maybe, maybe not. Google Bear Raid.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities